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Abstract 
The characteristics of boron neutron capture therapy (BNCT) for cancer treatment demand, in addition to sufficient 
fluxes of epithermal neutrons, proper conditions of the neutron sources—compact layout, flexible operation, 
compatibility with hospital setting, etc. These requirements are best satisfied by compact accelerator-driven sources 
(CANS). We discuss the trade-offs among different CANS options and the needed R&D in order to advance BNCT 
to an acceptable level of practical prevalence and cancer treatment scope. We focus our attention on compact neutron 
generators (CNGs) which are the most compact and least expensive. We argue that the usefulness of D-D CNGs for 
preliminary studies, in spite of the substantial lower fluxes, can be augmented by high-performance beam-shaping 
assemblies and discoveries of superior 10B-containing cancer-cell seeking drugs. The plausibility of BNCT treatment 
of breast cancer using neutrons from a DD-109 CNG (Adelphi Technology, Inc.) is assessed by calculating the 
distribution of photon equivalent dose on a breast phantom using Monte-Carlo (MCNPX) simulations. 
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1. Introduction 
Boron neutron capture therapy (BNCT) which bases a cancer treatment on the neutron-capture reaction 
of 10B(n, D)7Li is by far the most researched modality among all the possible neutron-capture therapeutic 
processes. The emitted D-particle and 7Li nucleus from each neutron capture have high linear energy 
transfer (LET) of ~100 times of those of X-, J- and E-rays and a short mean range, ~9 and ~5 Pm, 
respectively, that is comparable to the typical dimension (~10 Pm) of a cell. If sufficient amount of 10B 
can be delivered and concentrated on the surface or preferably in the interior of only the cancerous tumor 
cells, neutron irradiation on the cancer will generate a superlative relative biological effectiveness (RBE) 
on killing the tumor cells while preserving the normal tissue. Clearly, BNCT is a complex, multi-
disciplinary enterprise, encompassing the fields of neutron sources and neutronics, pharmaceuticals, 
medical imaging, radiobiology, and clinical planning and implementation. In spite of a long history of 
research first conceived in 1930s and of experimentation in early 1950s, progress of BNCT so far has 
fallen behind the photon- and ion-beam therapies in practical prevalence and treatment scope. For 
example, preclinical trials and treatments to date have taken place only at improvised neutron-delivery 
stations at fission-reactor sources that devote not entirely to medical purposes. Only two 10B-carrying 
drugs have been approved for treating head and neck cancers. The lack of proper neutron sources that can 
be integrable to the infrastructure of hospital or clinical facilities is a major problem.  
The use of accelerator-driven neutron sources in lieu of nuclear reactors in principle offers several 
favorable characteristics such as the fissile-material-free operation, easy on/off switch of neutron 
production, and neutron energies adjustable to treat cancers in different organs. Moreover, recent 
advances in accelerator and neutronics technologies have led to the realization of increasingly compact, 
relatively low cost, reasonably intense neutron sources, readily to lend themselves to a variety of 
applications including BNCT. Therefore, opportunities now exist for the development of innovative 
compact accelerator-driven neutron sources (CANS) commissioned to a broad scope of cancer treatments 
by BNCT. This paper first discusses the trade-offs between several plausible CANS options with respect 
to the BNCT characteristics and requirements and then focuses on the newly improved compact neutron 
generators (CNGs) that are based on the deuteron-deuteron (D-D) fusion reaction. We note that the not 
yet sufficient neutron flux of CNGs can be augmented by improvements of the neutron moderator design 
and beam optics as well as discoveries of novel, high 10B-content cancer-cell seeking drugs so that proof-
of-principle studies and preliminary testing of BNCT treatment of breast cancer can commence. Naturally, 
networking the research communities and commercial enterprises toward a unified goal is a key factor for 
the success due to the multidisciplinary nature of BNCT. 
2. Neutron-generating reactions of CANS 
Because thermal neutrons are efficiently captured by 10B and fast neutrons impose negative biological 
effects to healthy cells over a long penetrative distant, BNCT should be administered with epithermal 
neutrons (eV to keV range). Consequently, a consideration of the neutron yields and emission energies of 
various neutron-generating reactions, as given in Table 1, leads to the conclusion that the reactions of 
7Li(p, n)7Be, 9Be(p, n)9B, 9Be(d, n)10B, and 13C(d, n)14N are most favorable. The design and engineering 
of CANS based on these reactions for BNCT have to confront a variety of technical issues. For superficial 
cancers (<5 cm deep), an ideal situation would be operating a CANS at a projectile energy just above the 
threshold energy of the reaction, if any, so as to produce a maximum amount of ‘soft’ epithermal neutrons 
in the forward direction (in the laboratory frame of reference) with minimum J-radiation, fast neutrons, 
and daughter nuclei in the beam. This implies the 7Li(p, n)7Be reaction being the best candidate. However, 
the flammable and low-melting-point Li target presents a number of technical challenges such as heat 
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removal and protecting the target from radiation damage by the proton beam, which have yet to be 
overcome. The second best option is the 9Be(p, n)9B reaction which is founded on a proven accelerator-
target technology to produce a good neutron fluxes. Proton linac systems designed for BNCT application 
are available commercially (e.g., by AccSys, USA). More details about a BNCT facility based on this 
proton accelerator-beryllium neutron target currently under construction in Japan can be found in a 
accompanying paper in this proceedings [1]. The alternative of using deuterons as projectile on a 
beryllium target is suboptimal in terms of neutron flux production. The option of deuterons on carbon 
targets is a future possibility pending more technical development.   
In general, the technologies of the front-end proton or deuteron accelerators are well established 
although their compactness and efficiency can be improved. But the neutron target system and the beam-
shaping assembly (BSA) require substantially more research. The operation of CANS requires no 
nuclear-facility qualification and the compactness of the entire system including the mandated measures 
for radiation protection affords uncomplicated installation and routine running at hospitals or medical 
centers (see Table 1).  
 
Table 1. Neutron-generating reactions and CANS suitable for BNCT. 
Reaction E projectile (MeV) 
E threshold 
(MeV) 
<E neutron> 
(MeV) 
Neutron yield 
(n/mA/s) 
Accelerator/target;  
approx. linear dimension & cost  
7Li(p,n)7Be 2.5 1.88 ~0.6 9.09 x1011 p-linac/lithium (technical challenging); ~5 m & ~$5+M 
9Be(p,n)9B ~4-20 2.06 ~1.6-8 0.5-1.2 x1012 p-linac/beryllium (achievable);  ~5-10 m & ~$5-10M 
9Be(d,n)10B 1.5 0 1.66 3.3 x1011 p-linac/beryllium (achievable);  ~5 m & ~$5M 
2H(d,n)3He 0.15 0 2.5 ~2 x109 neutron generator/d-Ti;  ~1m & ~$0.2M 
3H(d,n)4He 0.15 0 14.1 ~5 x1010 neutron generator/d-Ti;  ~1m & ~$0.3M 
13C(d,n)14N 1.5 0 1.08 1.9 x1011 under study 
12C(d,n)13N 1.5 0.33 0.55 6 x1010 under study 
 
3. Compact neutron generators  
A CANS operating in the energy range of a few MeVs usually employs the radio-frequency 
quadrupole (RFQ) accelerator to build up the kinetic energy, at a typical rate of ~1 MeV per meter of 
RFQ segment, of the projectile particles generated by the ion source. This allows the overcome of 
reaction threshed, if any, and attaining the desirable neutron yield at a high projectile energy of the (p/d, 
xn) reaction. But the associated complexity, necessitating high RF power, high-vacuum beam transport 
and optics, a neutron target-moderator-reflector (TMR) station, the associated interfaces, and heavy 
shielding enclosing the beam path, engenders an intertwined structure which demand considerable capital 
investment and operation overhead (see Table 1).  
CNGs produce fast neutrons from the 2H(d, n)3He (D-D) or the 3H(d, n)4He (D-T) fusion reactions. A 
CNG accommodates the ion source, electron shield, acceleration structure and a target in a single housing, 
see layout in Fig. 1. Thus they are substantially smaller and less expensive (by factors of 1/50 to 1/1000) 
than accelerators/reactors. The drawback is the production of fast neutrons at considerably lower neutron 
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fluxes. The modern target uses a deuterium (D+) or tritium (T+) absorbing material such as titanium 
backed by liquid cooled copper. The titanium readily absorbs the D+ or T+ ions forming a titanium 
hydride.  Succeeding D+ or T+ ions strike these embedded ions and fuse, resulting in (d, d), (T, d) or (t, t) 
reactions and releasing fast neutrons.   
 
 
Fig. 1. A schematic layout of an Adelphi D-D CNG. 
 
Traditionally, Penning ion sources are used in most neutron generators. Adelphi neutron generators 
utilize the electron cyclotron resonance as a more efficient way of ionizing the deuterium gas. Such 
sources have been greatly improved in the last decade by K. Leung and his collaborators at the Lawrence 
Berkeley National Laboratory (LBNL) in the US [2]. A more modern source, the ECR ion source 
(ECRIS) can achieve plasma densities much higher than Penning or RF-driven ion sources at similar 
operation pressures (0.5–5  mT) and power consumption. The ECRIS is easy to use with no complicated 
ignition procedures, requiring pressure or matching network adjustments. The source’s low operation 
pressure prevents voltage breakdown in the acceleration region, resulting in more stable operation. The 
ECRIS production of high fraction (80–98%) atomic ions makes it possible for the generators to push the 
envelope of the available neutron yields above those of Penning-driven neutron generators. Since the 
microwaves are confined within the waveguide and the ion source cavity, no EMI noise, typical to the 
RF-driven ion sources, is present. With these new ion sources the operation of the generators has become 
simpler, making them more attractive for medical, industrial and security applications since trained 
technicians are in general not needed to operate the generator. 
Compact fusion generators offer perhaps the most inexpensive method for generating neutrons for 
BNCT. The individual D-D, single-ion beam generator is limited to a global yield of the order of 1011 n/s, 
while that of the D-T fusion generator can have a factor of 100 more yield for the same amount of high 
voltage power and ion-beam current. Neutron yield limitations are primarily due to target heating and 
high voltage power requirements to achieve higher yields. However, the D-D neutron generator offers a 
number of benefits that make it more useful and safer for a clinical setting. It uses non-radioactive 
deuterium gas, can be actively vacuum pumped, has a long lifetime and can be easily repaired; whereas, a 
D-T generator uses radioactive tritium, must be sealed, has a short lifetime and components in the 
generator head that cannot be easily repaired or replaced (they are tritium contaminated).  
The preference to ‘soft’ epithermal neutrons is good for superficial cancers like tumors in the brain and 
the neck. For deeper cancers, for example, to reach a depth of ~10 cm, neutrons of energies ~1 MeV are 
needed [3]. Therefore, the moderately high energy neutrons (2.45 MeV before moderation) from a D-D 
CNG become useful, better than the very fast neutrons (14.1 MeV) from a D-T CNG.  
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4. Neutronics performance for BNCT using an Adelphi DD-109 CNG 
Cancer in humans is an assortment of more than 200 diverse diseases that can arise in all tissues and 
organs. According to United States Cancer Statistics (USCS) of year 2100, breast cancer tops 18% of all 
cancer incidence in females. More alarming is the high risk of acquiring breast cancer in a lengthy period 
over the life span (from 20 year of age up). Here, we report an assessment of the photon equivalent dose 
on breast cancer treatment by BNCT with neutrons supplied by an Adelphi DD-109 CNG in conjunction 
with a BSA optimized by computer simulations using the Monte Carlo radiation transport code (MCNPX).  
Firstly, we configure a neutron production zone in the simulation by adopting the dimensions of the 
cylindrical vacuum chamber of Adelphi’s DD-109 CNG, with a Ti-target emits isotopically 2.45-MeV 
neutrons at the center [4]. Next, we model the BSA that consists of a sleeve made of iron around the 
neutron production zone, a connecting block made of AlF3, and an enclosing structure of lead, as shown 
schematically in Fig. 2. This rationale of a two-stage neutron slowing-down, first by Fe and then by AlF3, 
in conjunction with the Pb as a reflector and gamma shield was tested by the MCNPX simulations. The 
calculated neutronic performance was monitored as the dimensions of the Fe, AlF3 and Pb components 
are varied until an optimal performance was achieved. No beam collimator was implemented but a layer 
of Li was added as additional thermal neutron delimiter of the exit beam. The final thickness of the Fe 
and AlF3 structure is 10 and 25 cm, respectively (see Fig. 2). Fig. 3 shows the leakage neutron spectrum 
per unit lethargy (logarithmic energy decrement) tallied at the position of 10 cm from the Li layer (inside 
the phantom, see Fig. 2). It shows that the BSA is successful in the slowing-down of the 2.45-MeV fast 
neutrons, resulted in a neutron energy distribution peaked at ~10 keV with a sharp suppression of fast 
neutrons at high energies.  
Finally, we conduct a rudimentary calculation of the dosimetry on a breast phantom placed at the exit 
of the beam (Fig. 2). The elemental composition of the breast tissue phantom (density: 1.02 g/cm3 with H 
10.6%wt, C 33.2%wt, N 3.0%wt, and O 52.7%wt) was taken from the ICRU 46 report [5]. The 10B 
concentration in the tumor and the healthy tissue was assumed to be 60 ppm and 12 ppm, respectively. 
The CBE (compound biologic effectiveness) factors, 1 for gamma dose, 3.2 for nitrogen, carbon, and 
oxygen, and the fast neutron dose, 1.3 for boron in healthy tissue and 3.8 for tumor, were applied. The 
dosage in terms of RBE Gy as a function of depth in the breast tissue (phantom) is shown in Fig 4. 
Assuming a tumor depth that matches the peak total dose, the maximum dose in the tumor, about 3.6 × 
10-12 RBE Gy/h/ DD neutron/s, is about three orders of magnitude higher than the dose in the normal 
tissue. This maximum dose corresponds to 72 RBE Gy of one-hour irradiation by a DD neutron source 
with a mominal intensity of 2 × 1013 n/s, which is comparable to the maximum dose per hour (66.8 RBE 
Gy) for recurrent breast cancer reported in [7]. Therefore, the current neutron flux (~2 × 109 n/s) of the 
DD-109 CNG is about 10,000 times lower than the ideal condition for treatment of breast cancer.  
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Fig. 2 (top). A schematic layout of the BSA and the breast phantom. Fig. 3 (left). The neutron lethargy spectrum tallied at the 
position of 10 cm from the Li layer (inside the phantom), normalized to per DD-09 CNG neutron. Fig. 4 (right). Depth dose 
distribution in the tissue of the breast phantom. 
5. Conclusion and outlook 
The cost of cancer in terms of human suffering and economic impairment is enormous. By any 
measure revealed by cancer statistics such as the data collected by the National Cancer Institute (NCI) of 
the US, very little progress has been made in cancer treatment and prevention, let alone of gaining the 
upper hand on the War on Cancer that was declared by the National Cancer Act of 1971. BNCT is one of 
the promising weapons deserving honing for the fight against cancer to which advance in CANS will be a 
key contributing factor. We focus on the fusion-based D-D CNGs mainly for the reasons of i) the recent 
improvement on the device, ii) their compactness, transportability and commercial availability, and iii) 
the substantial saving in capital investment and operation overhead. All of these point to a plausible fast-
track approach of a BNCT research program. The readiness of neutron supply by CNGs, albeit of a 
moderate flux, will permit a concentrating effort on improving neutronic performance of the BSA, 
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dosimetry measurements, and drug effectiveness evaluation. Furthermore, the research data can be scaled 
up to provide an assessment of future high-flux neutron experiments. 
We are working with a number of research partners at universities, government labs, and high-tech 
companies on various fronts of BNCT treatment of breast cancer: i) R&D of higher-flux CNGs, including 
an approach of multi-beam configuration (Adelphi Technology, Inc.) [4], ii) Building the BSA and 
experimental platform in collaboration with computer simulations (in-house engineering & IoP-CAS), iii) 
development of novel 10B-containing drugs (Jinan University & Sun Yat-Sen University) [7], iv) 
dosimetry and health physics studies (The University of Hong Kong and University of Utah) [8], and v) a 
discussion of a new protocol of clinical management for BNCT (International BNCT Society) [9]. The 
last three items (iii-iv) have produced encouraging results although they are not rigorous enough to 
present here. It is our hope that these combined efforts will lead to expedient preclinical trials of BNCT 
for an expanded scope of cancer treatments. 
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